The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 357:605-607 August 9, 2007 Number 6
NextNext

Rituximab and Pemphigus — A Therapeutic Advance
Luis A. Diaz, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Joly, P.
-PubMed Citation
Pemphigus vulgaris and pemphigus foliaceus are rare autoimmune blistering diseases of obscure causes. The scientific bases for the therapy of these disorders have evolved in the past 60 years. Landmark studies demonstrated that intraepidermal blisters were subcorneal in pemphigus foliaceus1 and suprabasilar in pemphigus vulgaris2,3 and suggested that an ongoing process of epidermal-cell detachment (acantholysis) led to blister formation. Armed with this limited information, dermatologists in the 1950s began to use systemic steroids to treat these diseases. Before the use of corticosteroids, the diagnosis of pemphigus carried a poor prognosis; it was believed that if a patient survived for more . . . [Full Text of this Article]


Source Information

From the Department of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill.



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.